je.st
news
At 2014 San Antonio Breast Cancer Symposium three new Myriad studies highlighted
2014-12-13 11:24:24| Biotech - Topix.net
Myriad Genetics, Inc. has announced results from a new study that demonstrated the ability of the myRisk Hereditary Cancer test to detect 105 percent more mutations in cancer causing genes than conventional BRCA testing alone. The Company also presented two key studies in triple negative breast cancer that show the myChoice HRD test accurately predicted response to platinum-based therapy in patients with early-stage TNBC and that the BRACAnalysis molecular diagnostic test significantly predicted response to platinum-based drugs in patients with metastatic TNBC.
Tags: san
studies
antonio
cancer
Category:Biotechnology and Pharmaceuticals